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Abstract 
Background: Malaria remains one of the most serious infections for travellers to tropical countries. Due to the lack of 
harmonized guidelines a large variety of treatment regimens is used in Europe to treat severe malaria.
Methods: The European Network for Tropical Medicine and Travel Health (TropNet) conducted an 8‑year, multicen‑
tre, observational study to analyse epidemiology, treatment practices and outcomes of severe malaria in its member 
sites across Europe. Physicians at participating TropNet centres were asked to report pseudonymized retrospective 
data from all patients treated at their centre for microscopically confirmed severe Plasmodium falciparum malaria 
according to the 2006 WHO criteria.
Results: From 2006 to 2014 a total of 185 patients with severe malaria treated in 12 European countries were 
included. Three patients died, resulting in a 28‑day survival rate of 98.4%. The majority of infections were acquired in 
West Africa (109/185, 59%). The proportion of patients treated with intravenous artesunate increased from 27% in 
2006 to 60% in 2013. Altogether, 56 different combinations of intravenous and oral drugs were used across 28 study 
centres. The risk of acute renal failure (36 vs 17% p = 0.04) or cerebral malaria (54 vs 20%, p = 0.001) was significantly 
higher in patients ≥60 years than in younger patients. Respiratory distress with the need for mechanical ventilation 
was significantly associated with the risk of death in the study population (13 vs 0%, p = 0.001). Post‑artemisinin 
delayed haemolysis was reported in 19/70 (27%) patients treated with intravenous artesunate.
Conclusion: The majority of patients with severe malaria in this study were tourists or migrants acquiring the infec‑
tion in West Africa. Intravenous artesunate is increasingly used for treatment of severe malaria in many European 
treatment centres and can be given safely to European patients with severe malaria. Patients treated with intravenous 
artesunate should be followed up to detect and manage late haemolytic events.
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Background
Around 5200 cases of malaria are imported to EU coun-
tries per year, of which up to 10% progress to severe 
malaria [1]. Because most patients with imported 
malaria are not semi-immune, progression to severe 
malaria is considerably more frequent in non-endemic 
than in endemic countries. Non-immune patients carry 
a substantial risk of suffering from complications of the 
infection itself or from complications associated with 
intensive care treatment.
The epidemiology of imported severe malaria is chang-
ing. In addition to tourist or business travellers to tropical 
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regions, migrants visiting friends and relatives (VFR) in 
their previous home country are increasingly affected 
[2, 3]. This population is less likely to seek pre-travel 
advice and to take anti-malarial prophylaxis [4, 5]. Most 
migrants are not aware of the waning of semi-immunity 
against malaria when they travel to their home countries.
Guidelines to define and to treat severe malaria have 
undergone major changes in the past decade at inter-
national and national levels. Criteria for the definition 
of severe malaria were amended by the World Health 
Organization (WHO) in 2006, 2010 and 2015, par-
ticularly with regard to the definition of hyperparasi-
taemia [6], and numerous classification and treatment 
recommendations still exist across European countries. 
Another challenge is the transition from intravenous qui-
nine to intravenous artesunate as first-line treatment for 
severe malaria. Despite its superior potential to save lives 
and shorten duration of hospital and intensive care unit 
(ICU) treatment [7–10], many difficulties with regard to 
registration, availability and quality of artesunate have to 
be overcome before it will be easily available and widely 
used outside of specialist referral centres for tropical 
medicine in Europe. The pathophysiology of late haemo-
lytic reactions occurring 2–6 weeks after treatment is not 
fully understood and harmonized guidelines for follow-
up care of patients receiving this drug in Europe need to 
be developed [11, 12].
Data on epidemiology and treatment of imported 
severe malaria across Europe, together with a ‘road map’ 
towards drug approval of intravenous artesunate for the 
treatment of severe malaria in non-endemic countries are 
needed to eventually improve and harmonize treatment 
recommendations. Data are however available only from 
national cohorts and case registries. The European Net-
work for Tropical Medicine and Travel Health (TropNet) 
[13] conducted an 8-year, multi-centre, observational 
study to analyse epidemiology, treatment practices and 
outcome of severe malaria in its member sites across 12 
European countries.
Methods
This multicentre observational study was performed 
among member sites of TropNet. All patients with 
microscopically confirmed severe falciparum malaria, 
according to the 2006 WHO criteria treated at one of the 
participating TropNet centres between 2006 and 2014, 
were eligible. Physicians at participating TropNet centres 
were asked to report pseudonymized retrospective data 
on demographic characteristics, medical and travel his-
tory, clinical presentation, anti-malarial drug regimen, 
supportive treatment, parasitaemia before and under 
treatment, complications under treatment, adverse drug 
reactions, outcome and follow-up during 28  days from 
all patients treated for severe malaria at their centre. The 
treatment remained the responsibility of the treating 
physician. Parasite clearance time was defined as time 
to the first thick blood smear without evidence of asex-
ual parasites after initiation of anti-malarial treatment. 
For the analysis of this dataset, post-artemisinin delayed 
haemolysis (PADH) was defined as a decrease in haemo-
globin together with signs of haemolysis (elevated LDH) 
after completion of anti-malarial treatment and complete 
parasite clearance. Electronic case report forms were 
used for data entry and transmission to the coordinating 
centre at Charité University Hospital, Berlin, where data 
were transferred into a database and checked manually 
for plausibility.
The primary objective of this study was to assess clini-
cal presentation, treatment and outcome in patients 
with imported severe malaria. Descriptive statistics was 
performed on sociodemographic, medical, treatment, 
and outcome data. Mann–Whitney U test (two groups, 
continuous data), Fisher exact test (two groups, categori-
cal data), or Kruskal–Wallis test (>two groups continu-
ous data) at a two-sided significance level of α  =  0.05 
were used for comparative analysis. Analysis of variance 
(ANOVA) for continuous data and Pearson Chi squared 
test for categorical data were used to test the distribution 
of demographical characteristics of patients over time. 
Data are displayed as median (±interquartile range). Sta-
tistical analysis was performed using JMP (JMP 7.0, SAS 
Institute Inc, NC, USA).
The study was approved by the Ethics Committee of 
Charité University Hospital, Berlin. Ethical clearance for 
transfer of retrospective pseudonymized patient data was 
sought at participating Tropnet centres according to local 
regulations.
Results
From 2006 to 2014, 190 patients with severe falciparum 
malaria were reported by the participating 28 TropNet 
centres from 12 European countries. After excluding 
three cases without documented criteria for severe 
malaria and two cases with double reporting, 185 data-
sets were available for analysis. The number of patients 
per centre ranged from one to 31 patients. The number of 
reported patients per country is shown in Table 1.
Demography, place of infection and anti‑malarial 
prophylaxis
Demographic data are shown in Table  2. The propor-
tion of female patients was comparatively small (29%). 
The majority of patients (106/185, 57%) were of Euro-
pean origin without history of migration. Tourism was 
the main purpose of travel in Europeans (54/106, 51%), 
whereas VFRs were the predominant purposes of travel 
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in patients with history of migration (55/68, 81%). Euro-
pean patients were on average older than patients with 
history of migration [median age 47 (IQR 33–57) vs 36 
(IQR 27–45) years, p  <  0.0001]. All malaria infections 
were acquired in Africa with the exception of two cases 
from Central America. By far the largest proportion of 
infections came from West Africa (109/185, 59%), fol-
lowed by Central Africa (40/185, 22%), where Cameroon 
was the country with the highest number of imported 
cases (21/185, 11%, Fig. 1). VFR patients acquired malaria 
infections almost exclusively in West Africa, whereas 
European tourists acquired infections also in the tourist 
destinations of East Africa (Fig. 2). There was no change 
in age (F =  0.84, p =  0.5), gender (p =  0.11), origin of 
patients (p =  0.54) or purpose of travel (p =  0.10) dur-
ing the 8-year course of the study. Almost 9 out of 10 
patients (162/185, 88%) had not taken any anti-malarial 
chemoprophylaxis. Among 23 patients who took anti-
malarial chemoprophylaxis, only six fully adhered to the 
prescribed regimen.
Clinical presentation
Clinical manifestations and laboratory findings leading 
to classification as severe malaria are shown in Table 2. 
Median baseline parasitaemia was 6.5% (IQR 4–11) and 
hyperparasitaemia (≥5%) was the most common crite-
rion of severe disease, followed by jaundice, which was 
a criterion for severe malaria in this study according to 
WHO guidelines as of 2006. Eight patients with jaun-
dice had no other vital organ dysfunction and would not 
have been classified as severe disease according to WHO 
guidelines as of 2010 [14].
Underlying chronic conditions were found in 43% 
of patients (63/185), of which hypertension was the 
most frequent (9%, 16/185). Seven per cent of patients 
(13/185) were HIV positive. The majority of patients 
(119/185, 64%) met one or two criteria of severe malaria, 
whereas 8% (17/185) met more than four criteria. 
Patients ≥60 years presented, on average, with more cri-
teria for severe malaria than younger patients (median 3 
vs 2, p = 0.02). Table 3 shows the risk of presenting with 
a particular criterion of severe malaria according to age 
(≥60 years vs younger patients). There was no difference 
in type and number of criteria for severe malaria among 
patients of European versus non-European origin with 
the exception of a lower median baseline parasitaemia (7 
vs 5%, respectively, p = 0.04).
Anti‑malarial treatment
Intravenous quinine was the main first-line treatment in 
93/185 patients (50%) whereas intravenous artesunate 
was used in 63/185 patients (35%). Seven patients (4%) 
received intravenous quinine and artesunate in combina-
tion. Table 4 gives an overview of the drugs and drug com-
binations used as follow-on treatment after intravenous 
therapy. Altogether 56 different combinations of intrave-
nous and oral drugs were used across the different centres.
The proportion of patients treated with intravenous 
artesunate increased steadily during the course of the 
study from 27% (8/30) in 2006 to 60% (18/30) in 2013. 
In 22/185 patients (12%) only oral first-line treatments 
were given such as oral quinine (n  =  16, exclusively in 
Italy), oral atovaquone-proguanil (n = 1, in a patient with 
HIV), and oral artemether–lumefantrine (n = 5). Patients 
treated with oral anti-malarials presented exclusively 
with hyperparasitaemia (n  =  19, median parasitaemia 
7%, range 5–8%) and/or jaundice (n =  6) as criteria for 
severe malaria and had no co-morbidities (except the one 
patient with HIV).
Choice of the first-line treatment was very heterogene-
ous across different sites and was mainly dependent on 
the country where the patient was treated. Centres in 
Norway, The Netherlands and Belgium reported treat-
ment almost exclusively with intravenous artesunate, 
whereas the participating treatment centres in Spain 
and France used intravenous quinine in the majority of 
reported cases (9/12, 75% and 44/50, 88%, respectively).
Concomitant and supportive treatment
An overview of supportive treatments is given in 
Table  5. Antibiotic therapy (44% of patients) and eryth-
rocyte transfusion (21% of patients) were the most com-
mon. Erythrocyte exchange transfusion was performed 
in 8/185 (4%) patients at seven centres in Italy, Spain, 
Table 1 Number of  study centres and  reported cases 
per country (n = 185)
Country Number 
of centres
Number 
of reported  
cases
% of total 
number 
of cases
Austria 2 7 4
Belgium 1 19 10
Denmark 2 14 7
France 2 52 28
Germany 7 15 8
Italy 5 50 27
Netherlands 1 4 2
Norway 1 7 4
Portugal 1 1 1
Spain 2 12 6
Switzerland 3 3 2
UK 1 1 1
Page 4 of 11Kurth et al. Malar J  (2017) 16:57 
Belgium, and The Netherlands. Seven of these patients 
were treated with intravenous quinine and one with intra-
venous artesunate. Baseline parasitaemia was >10% in all 
these patients (median 18%, IQR 10–27). Erythrocyte 
apheresis was performed in 5/185 patients (3%) at two 
centres (Vienna, Austria and Leiden, The Netherlands). 
Parasitaemia was >15% in all these patients (median 19%, 
IQR 18–28) and all five patients were treated with intra-
venous artesunate.
Adverse drug reactions
Adverse drug reactions were reported in 27/100 patients 
(27%) treated with intravenous quinine, and in 21/70 
(30%) patients treated with intravenous artesunate. None 
of them was fatal. Cinchonism was the most common 
adverse drug reaction in patients treated with intrave-
nous quinine (19/100, 19%). It was rated as mild in 17/19 
cases and moderate in 2/19 cases by the treating physi-
cian. Hypoglycaemia occurred in 4/100 patients (4%) and 
cardiac arrhythmias in 1/100 patient (1%) treated with 
intravenous quinine.
In patients treated with intravenous artesunate, PADH 
was reported in 19/70 patients (27%), a finding which 
first became known during the study period in the year 
2011. Onset of PADH was reported during days 10 to 
14 (median 14) and median duration of haemolysis was 
reported to be 14 (IQR 8–18) days. Three patients (15%) 
with PADH received blood transfusions, with 2 patients 
(10%) re-hospitalized (for 3–5  days, respectively). In 1 
patient, PADH was reported after therapy with only oral 
artemether–lumefantrine. This patient and some of the 
other patients with delayed PADH have already been 
reported elsewhere [15–17].
Table 2 Characteristics of  patients with  severe malaria 
(n = 185 patients in all categories)
Data are number of patients, unless indicated otherwise
COPD chronic obstructive pulmonary disease, HIV Human immunodeficiency 
virus
a  Patients with reported adherence to chemoprophylaxis only
b  Chloroquine-proguanil was taken for travel to Togo in 2007 and Burkina Faso 
in 2010
c  Hyperparasitaemia >2 and >10% were not used as criteria for severe malaria 
in this study according to WHO guidelines 2006 and are shown for informational 
purposes only
d  Clinical jaundice was used as criterion for severe malaria in this study 
according to WHO guidelines 2006
Characteristics n (median) % [IQR]
Gender
 Male 132 71
Age
 Age in years (42) [31–52]
 ≥60 years 22 12
 ≤18 years 10 5
Origin of patients
 European, no history of migration 106 57
 Immigrant/history of migration 68 37
 Visitor from endemic country 11 6
Anti‑malarial chemoprophylaxis
 None 162 88
 Non‑adherence to prescribed regimen 17 9
 Doxycyclinea 2 1
 Chloroquine‑proguanila,b 2 1
 Mefloquinea 1 1
 Atovaquone‑proguanila 1 1
Criteria leading to classification as severe malaria
 Hyperparasitaemia >5% 132 71
 Hyperparasitaemia >10%c 55 30
 Hyperparasitaemia >2%c 154 83
 Jaundiced 81 44
 Impaired consciousness/coma 46 25
 Acute renal failure 36 19
 Liver function test >3 times upper normal 36 19
 Circulatory collapse/shock 27 15
 Anaemia <8 g/dl 27 15
 Respiratory failure 22 12
 Spontaneous/abnormal bleeding 13 7
 Acidosis 9 5
 Hypoglycaemia <40 mg/dl 6 3
 Multiple convulsions 3 2
Number of criteria for severe malaria met by individual patients
 1 59 32
 2 60 32
 3 30 16
 4 19 10
 5 10 5
 >5 7 3
Underlying co‑morbidities
 Any 63 43
 Hypertension 16 9
 HIV 13 7
 Diabetes 10 5
 Chronic heart disease 8 4
Characteristics n (median) % [IQR]
 Hepatitis 3 2
 COPD 2 1
 Other chronic conditions 11 6
Table 2 Continued
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In one patient, an acute cerebellar syndrome (ataxia, 
dysarthria, dysmetria, adiadochokinesis) was described 
beginning 3  days after the end of anti-malarial treat-
ment (day 10). The patient had not shown any neurologi-
cal symptoms during the acute phase of malaria and had 
been treated with a loading dose of intravenous quinine 
on day 1, intravenous artesunate from day 1 to 4 and oral 
artemether–lumefantrine from day 5 to 7. An MRI scan 
and lumbar puncture showed no abnormalities. Due to 
persistence of symptoms, the patient received physi-
otherapy until ten weeks after anti-malarial treatment, 
where neurological symptoms steadily improved. Com-
plete recovery was reported 7  months after the malaria 
episode.
Outcome
Three patients died, two of European origin and one 
with history of migration, resulting in a 28-day survival 
rate of 98.4%. All three patients had been treated with 
intravenous quinine and one of them also with intrave-
nous artesunate simultaneously. All deaths occurred 
within the first 3 days after admission. All three patients 
had presented with hyperparasitaemia (9, 10 and 40%) 
and respiratory distress requiring mechanical ventila-
tion. Respiratory distress with the need for mechanical 
ventilation was significantly associated with the risk of 
death in the study population (13 vs 0%, p = 0.001). Of 
note, two of the patients who died were 22–34  years of 
age, respectively, and had no underlying co-morbidities. 
One of them had a history of migration. The third patient 
was 70 years of age, suffered from a pre-existing chronic 
cardiomyopathy and died from therapy-refractory shock.
In 76% of patients (117 of 153 patients with available 
data) treatment took place in an ICU, where the median 
length of stay was three (IQR 2–5) days. The median 
length of inpatient treatment was 7  days (IQR 5–9). 
Median time to 99% parasite clearance was 48  h (IQR 
24–72, n =  126) and median time to complete parasite 
Fig. 1 Countries where malaria infections where acquired (n = 185). Countries and number of cases per country are shown. Gray‑scale colour cor‑
responds to the proportion of cases acquired in the respective country
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clearance, was 72 h (IQR 60–120, n = 104). Data show-
ing shorter parasite clearance time and shorter ICU and 
inpatient treatment in patients treated with intrave-
nous artesunate compared to intravenous quinine were 
reported elsewhere [8]. The 22 patients who received oral 
anti-malarial treatment had comparatively long median 
99% parasite clearance and complete parasite clear-
ance times (72  h, IQR 48–72, and 120  h, IQR 84–144, 
respectively). There were no documented early or late 
parasitological failures.
Among 46 patients with cerebral malaria, six had neu-
rological sequelae at discharge such as confusion, dys-
phasia, ataxia, and imbalance. In four patients (2/25 
treated with artesunate vs 2/21 treated with quinine) con-
fusion and ataxia persisted at day 28. Among 36 patients 
with acute renal failure at presentation, 13 (36%) patients 
Fig. 2 a Countries where European tourist travellers acquired malaria (n = 54). Colour intensity corresponds to the proportion of cases acquired 
in the respective country. b Countries where visiting friends and relatives travellers acquired malaria (n = 55). Colour intensity corresponds to the 
proportion of cases acquired in the respective country
Table 3 Risk of presenting with particular criteria of severe malaria according to age ≥60 versus <60 years
Data are number of patients (%)
Patients ≥60 years n = 22 Patients <60 years n = 163 p value
Cerebral malaria 12 (54) 34 (21) 0.001
Acute renal failure 8 (36) 28 (17) 0.04
Hyperparasitaemia 17 (77) 120 (73) 0.8
Jaundice 8 (36) 73 (44) 0.5
Liver function test >3 times upper normal 7 (31) 29 (17) 0.15
Shock 6 (27) 21 (13) 0.1
Anaemia 3 (14) 24 (15) 1.0
Respiratory failure 3 (14) 19 (12) 0.7
Acidosis 2 (9) 7 (4) 0.29
Spontaneous bleeding 3 (13) 10 (6) 0.19
Hypoglycaemia 1 (5) 5 (3) 0.53
Multiple convulsions 0 (0) 3(2) 1.0
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had elevated creatinine levels at discharge, which had not 
been reported by the patient or documented in medical 
charts before malarial infection. In nine of these patients 
(4/17 treated with artesunate vs 5/16 treated with qui-
nine) elevated creatinine levels persisted after day 28. 
Two patients suffered from necroses of fingers and toes 
as sequelae of vasopressor therapy during malaria.
Among eight patients with jaundice as only criterion 
for severe malaria, who would not have been classified 
as severe according to WHO 2010 criteria, none experi-
enced documented complications of treatment or seque-
lae, seven were not treated at an ICU and patients had 
a comparably short median length of stay in hospital of 
4 days (IQR 4–6).
Discussion
Imported malaria remains a relevant clinical problem 
due to the rapid potential progression to severe and life-
threatening disease in non-immune patients. This study 
presents clinical and treatment data from 28 centres of 
the TropNet from 12 countries, one of the largest data-
bases collected on this patient population to date. Previ-
ous studies on severe malaria in Europe are only available 
either at centre [18–20] or country [3, 21–23] level.
Anti‑malarial treatment—intravenous artesunate
Intravenous artesunate has been shown to improve sur-
vival in patients with severe malaria in endemic areas, 
with particular benefit for patients with high parasitae-
mia [>10% infected red blood cells (RBCs)] [7, 9, 10]. A 
randomized, controlled trial to confirm superiority of 
artesunate over quinine in non-endemic areas would be 
unethical. Other benefits of treatment with intravenous 
artesunate such as shorter ICU and hospital treatment 
were clearly demonstrated in European patients [8].
Quinine is still widely used in Europe, but the rate of 
patients receiving intravenous artesunate almost doubled 
in the 8-year study period. In the final year 2014, every 
second patient received intravenous artesunate. Current 
surveillance data from national reference centres indicate 
that the proportion of patients treated with artesunate is 
further increasing, particularly in countries where par-
ticipating centres still reported frequent treatment with 
quinine during this study [24]. Although prospectively 
collected safety data from Europe is not available, this 
study adds to the evidence that artesunate is effective and 
can safely be used to treat patients in Europe. Artesunate 
is used in Europe despite considerable legal problems: 
The manufacturer of intravenous artesunate has been 
prequalified for good manufacturing practice-standard 
(GMP) by WHO [6], but the drug is not available in a 
European GMP-standard quality. It has an orphan des-
ignation for Europe by the European Medicines Agency 
since 2007, but no marketing authorization in Europe or 
in USA. Only in France, USA, Belgium, Denmark, and 
The Netherlands, named-patient programmes or similar 
Table 4 Initial drug combinations and follow-on treatment 
in  patients treated with  intravenous quinine or intrave-
nous artesunate for severe malaria
Data are number of patients and %
ACT artemisinin-based combination therapy, AP atovaquone-proguanil
a  Quinine, doxycycline or clindamycin were given for at least 7 days, n = 2 
patients died before initiation of subsequent therapy
b  Artesunate, doxycycline, clindamycin were given for at least 7 days
Patients n %
Treated with intravenous quinine 93
 Initial therapy
  Monotherapy 54 58
  Combination with doxycycline 33 36
  Combination with clindamycin 5 5
  Combination with mefloquine 1 1
 Follow‑on treatment
  Oral quinine 29 31
  Oral ACT 19 20
  Oral AP 11 12
  Nonea 34 37
Treated with intravenous artesunate 63
 Initial therapy
  Monotherapy 42 67
  Combination with doxycycline 13 20
  Combination with clindamycin 6 10
  Combination with mefloquine 2/ 3
 Follow‑on treatment
  Oral ACT 38 60
  Oral AP 17 27
  Oral quinine 2 3
  Mefloquine 3 5
  Noneb 3 5
Table 5 Supportive treatments used in European patients 
with severe malaria (n = 185)
Supportive treatments n %
Antibiotic therapy 82 44
Erythrocyte transfusion 38 21
Vasopressor therapy 24 13
Mechanical ventilation 24 13
 Invasive ventilation 18
 Non‑invasive ventilation 6
Haemodialysis and haemofiltration 20 11
Erythrocyte exchange transfusion 8 4
Erythrocyte apheresis 5 3
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protocols are in place, providing a legal basis for treating 
patients with this lifesaving drug [25, 26]. Until intrave-
nous artesunate receives approval from the European 
Medicines Agency and the US Food and Drug Admin-
istration, the legal context for physicians procuring and 
applying this drug in Europe will remain unsatisfactory. 
This study also highlights the differences in treatment 
practices and guidelines across Europe: from occasional 
use in some countries to exclusive use of artesunate to 
treat severe malaria in The Netherlands or Norway. This 
finding likely reflects the respective national legal frame-
work for using non-licensed drugs as well as national 
treatment recommendations [27]. The treatment of 
patients with intravenous artesunate and quinine in par-
allel, reported in seven patients, might also be based on 
judicial reasons: physicians might want to combine the 
most effective but unapproved drug (artesunate) with the 
approved and recommended standard first-line treatment 
(quinine) in order to avoid a legal risk [28]. No benefit of 
this combination has been shown compared to treatment 
with artesunate alone, whereas the frequency of adverse 
events increased [29]. A small number of patients were 
treated exclusively with oral anti-malarials in this study. 
These patients were less severely ill, including three 
patients with jaundice, as the only criterion for severe 
disease, who would not have been classified as severe 
according to the current WHO classification. No treat-
ment complications were reported for these patients, yet 
time to parasite clearance was comparatively long. Over-
all, there was a remarkable variety of altogether 56 differ-
ent combinations of intravenous and oral anti-malarial 
drugs reported. Harmonized, evidence-based European 
treatment guidelines would be useful to support clini-
cians in their choice of anti-malarial treatments.
Adverse drug reactions
Following the initial description of an episode of severe 
prolonged haemolysis after treatment of a patient with 
severe malaria with intravenous artesunate in Japan in 
2002 [30], late haemolytic reactions  2–6  weeks after 
treatment with intravenous artesunate were described 
in a case series in European patients in 2011 [12], and 
then confirmed in studies in European [15–17] and Afri-
can [31] patients. Removal of parasites from RBCs in 
the spleen, leaving behind a once-infected ‘pitted’ eryth-
rocyte with a shorter life span has been shown to be a 
potential mechanism causing late haemolysis [11], but 
the pathophysiology is not fully understood. The rate of 
haemolytic reactions and transfusions reported in the 
literature is variable depending on size, context, type, 
and setting of a study as well as on definitions of post-
treatment haemolysis; the results of the present study 
are generally in line with previous observations [12, 
16, 32] and late haemolysis can be expected to occur in 
approximately 20–30% of non-immune patients treated. 
As shown by the present data, a considerable proportion 
of them also receive blood transfusions. The results show 
once more that patients receiving intravenous artesu-
nate for treatment of severe malaria should be routinely 
observed for signs of haemolysis at least on days 7 and 
14 after treatment. An acute cerebellar syndrome 3 days 
after the end of anti-malarial treatment with intrave-
nous artesunate and oral artemether lumefantrine was 
reported in one patient. Although the reported time until 
complete resolution (7  months) is longer than in most 
cases reported in the literature; symptoms and time of 
onset are suggestive of post-malaria neurological syn-
drome [33].
Mortality
Mortality in this patient population was very low, reflect-
ing the high standard of intensive care in Europe. Previ-
ous single-centre and national studies reported mortality 
rates between 4 and 15% [3, 18, 19, 22, 34]. The propor-
tion of patients who had criteria of severe malaria associ-
ated with adverse outcome and death was comparable to 
other studies (Table 2) [2, 21, 34]. Mortality might have 
been biased by the fact that most reporting centres are 
tertiary care institutions with long experience in treat-
ing severe malaria. The study did not capture cases of 
severe malaria in smaller remote hospitals, where mor-
tality might be higher. The increasing use of intrave-
nous artesunate as main first-line treatment may also 
have contributed to reduce mortality, e.g., through rapid 
parasite clearance and shorter length of ICU and inpa-
tient treatment [7–9]. Age as risk factor for adverse out-
come of imported severe malaria has been shown by 
numerous studies [2]. In the present study, population 
patients ≥60 years were more likely to suffer from acute 
renal failure or from cerebral malaria, yet there was no 
increased case fatality among older patients.
Anti‑malarial chemoprophylaxis
Only 10% of patients with severe malaria had taken anti-
malarial chemoprophylaxis and very few of them had 
been fully compliant. These data suggest that correct 
anti-malarial prophylaxis can effectively prevent severe 
malaria in European travellers. Counselling of travellers 
on malaria prevention should be improved and coverage 
increased, particularly for travellers going to West Africa, 
where 60% of infections in this study were acquired. Lit-
tle is known about the proportion of European travellers 
who take prophylaxis. In a recent study only 60% of trav-
ellers from the UK to endemic areas used anti-malarial 
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chemoprophylaxis [35]. VFR travellers are a large trav-
eller population to Africa with different perceptions of 
malaria and its prevention [4, 5]. This may also influ-
ence the longer delay between onset of symptoms of 
malaria and presentation in hospital. The fact that 37% of 
patients in the present study had a history of migration 
clearly demonstrates the risk of these patients to suffer 
from severe malaria. Moreover, one of the patients who 
died was a 34  years old, otherwise healthy patient with 
history of migration. She presented with hyperparasitae-
mia, acute renal failure, jaundice, and respiratory failure. 
There was altogether no difference in symptoms and clin-
ical presentation between patients with or without his-
tory of migration, suggesting a waning of semi-immunity 
in migrants who left endemic areas [36].
Supportive treatments
Supportive treatments such as exchange transfusions and 
erythrocyte apheresis are a matter of controversy and 
their use is guided by national or local practices. Euro-
pean single-centre studies recently failed to demonstrate 
improved parasite clearance through whole blood or 
erythrocyte exchange, compared to patients treated with 
quinine or artesunate alone [37, 38]. Only 4% of patients 
received exchange transfusions in this study. It was per-
formed in only 7 out of 28 participating centres, mainly 
in patients treated with intravenous quinine. Likewise, 
only five patients in two centres received automated 
erythrocyte apheresis. With the increased use of intrave-
nous artesunate and its potential to rapidly reduce high 
parasite loads it needs to be determined whether par-
ticular patient populations might still benefit from these 
adjunctive treatments [39].
Limitations
This observational study has inherent limitations. As 
patient information was collected retrospectively in Trop- 
Net centres and not all patients treated may have been 
reported equally, selective under-reporting, e.g., for 
patients who died, may have occurred. Bias in reporting 
data on PADH must be assumed as the condition was not 
known at the beginning of the study and no universally 
accepted clinical definition exists to date. All TropNet 
centres are referral centres for tropical medicine and 
patient composition as well as treatment data may not 
fully reflect treatment practices and outcomes in non-
referral hospitals. Moreover, data reported by the par-
ticipating treatment centres may not always fully reflect 
treatment practices in the respective countries. For 
patients with elevated creatinine levels at the end of fol-
low-up, it cannot be ruled out that unknown or undoc-
umented elevation of creatinine had existed before the 
episode of severe malaria.
Conclusion
The data show that the majority of patients with severe 
malaria in Europe are tourists or migrants acquir-
ing infection in West Africa. Intravenous artesunate is 
increasingly used for treatment of severe malaria; it is the 
most effective drug and can be safely given to European 
patients with severe malaria. There is need for harmoni-
zation of guidelines for the treatment of severe malaria 
in Europe. Patients treated with intravenous artesunate 
should be followed up to detect late haemolytic events.
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